```html

Jod‑Related Thyrotoxicosis

Overview

Jod‑related thyrotoxicosis (also called iodine‑induced hyperthyroidism or Jod‑induced thyrotoxicosis) is a form of hyperthyroidism that occurs after a sudden increase in the body’s exposure to iodine. The excess iodine overwhelms the normal feedback mechanisms that keep thyroid hormone production in balance, leading to an over‑production of thyroxine (T4) and triiodothyronine (T3).

Although the condition can affect anyone, it is most common in:

• Adults over 40 years, especially women (≈ 70 % of reported cases).
• Patients with pre‑existing thyroid disease such as multinodular goiter or latent Graves disease.
• Individuals living in regions with borderline iodine deficiency who receive a sudden iodine load (e.g., after iodinated contrast studies, iodine‑containing medications, or dietary supplements).

In iodine‑sufficient areas, the incidence of jod‑related thyrotoxicosis is relatively low—estimated at 0.1–0.5 % after exposure to high‑dose iodinated contrast agents.<sup>1</sup> In iodine‑deficient regions, the risk can rise to 5–10 % after a single iodine load.

Symptoms

Symptoms result from excess circulating thyroid hormones and may mimic other forms of hyperthyroidism. They can appear within days to weeks after the iodine exposure.

General systemic signs

• Weight loss despite normal or increased appetite.
• Heat intolerance and excessive sweating.
• Tremor (fine shaking of the hands).
• Palpitations or rapid heartbeat (often > 100 bpm).
• Fatigue or muscle weakness, especially in the proximal muscles.
• Insomnia or difficulty staying asleep.

Cardiovascular manifestations

• Atrial fibrillation or other arrhythmias.
• Elevated systolic blood pressure with a widened pulse pressure.
• Heart failure in severe cases, particularly in older adults.

Gastrointestinal & metabolic signs

• Frequent bowel movements or diarrhea.
• Increased cholesterol turnover leading to low serum cholesterol.

Neuro‑psychiatric features

• Anxiety, irritability, or nervousness.
• Difficulty concentrating (“brain fog”).
• Rarely, acute psychosis or mania.

Other specific findings

• Goiter (enlargement of the thyroid) – especially in patients with multinodular disease.
• Ophthalmopathy (eye bulging) is uncommon in iodine‑induced disease but may appear if underlying Graves disease is present.

Causes and Risk Factors

The underlying mechanism is known as the Jod–Basedow phenomenon, first described in the early 20th century. An acute surge of iodine bypasses the Wolff‑Chaikoff “escape” phenomenon, leading to uncontrolled hormone synthesis.

Primary sources of excess iodine

• Iodinated contrast media used in CT scans, angiography, and interventional radiology.
• Iodine‑containing medications such as amiodarone (a class III anti‑arrhythmic), potassium iodide, and certain expectorants.
• Dietary supplements – high‑dose kelp, seaweed extracts, and multivitamins with added iodine.
• Medical procedures – nuclear medicine (radioactive iodine therapy) and thyroid surgery preparation.
• Environmental exposure – contaminated water in regions with industrial iodine discharge.

Risk factors that increase susceptibility

• Pre‑existing thyroid autonomy (multinodular goiter, toxic adenoma).
• Latent/early Graves disease.
• Age > 40 years.
• Female sex (≈ 2–3 × higher risk).
• Geographic iodine deficiency (borderline iodine intake).
• Renal insufficiency – reduced iodine clearance.

Diagnosis

Diagnosing jod‑related thyrotoxicosis requires a combination of clinical suspicion, laboratory testing, and imaging. The hallmark is a new‑onset hyperthyroid profile shortly after an identifiable iodine load.

Laboratory tests

• Serum TSH: Suppressed (usually <0.01 mIU/L).
• Free T4 and Free T3: Elevated (often 2–3 × the upper limit of normal).
• Thyroid antibodies (TSI, anti‑TPO, anti‑TG): Usually negative, helping to differentiate from Graves disease.
• Serum iodine (if available): Elevated > 300 µg/L, confirming large iodine load.
• Complete blood count, liver function tests, electrolytes: Baseline before treatment.

Imaging

• Radioactive iodine uptake (RAIU) scan: Low or normal uptake (< 5 %) in iodine‑induced thyrotoxicosis, contrasting with the high uptake seen in Graves disease.
• Thyroid ultrasound: May reveal multinodular goiter or autonomous nodules.

Diagnostic criteria (simplified)

1. Recent exposure to a high iodine load (within 2–8 weeks).
2. Suppressed TSH with elevated free T4/T3.
3. Low radioactive iodine uptake or normal imaging consistent with iodine excess.
4. Exclusion of other causes (Graves disease, thyroiditis, medication side‑effects).

Treatment Options

Treatment aims to control hormone excess, prevent complications, and address the underlying iodine source.

Immediate measures

• Discontinue iodine exposure – stop iodinated contrast, supplements, or offending medication if possible.
• Hydration and monitoring of renal function to aid iodine elimination.

Pharmacologic therapy

• Thionamides (first‑line):
  • Propylthiouracil (PTU) – 100–200 mg every 6–8 h; preferred if concurrent thyroid storm risk because it also blocks peripheral conversion of T4 → T3.
  • Methimazole (MMI) – 10–30 mg daily; easier dosing, fewer side effects; usually preferred for stable patients.
• Beta‑blockers (e.g., propranolol 20–40 mg q6h) to control tachycardia, tremor, and anxiety.
• Glucocorticoids (e.g., prednisone 40 mg daily) in severe cases to reduce conversion of T4 to T3 and mitigate thyroid storm.

Definitive or adjunctive procedures

• Radioactive iodine (RAI) therapy – Generally avoided during the acute excess iodine phase because uptake is low; may be used once iodine levels normalize.
• Thyroidectomy – Considered for large goiters, refractory disease, or when rapid control is essential (e.g., before cardiac surgery).

Lifestyle and supportive measures

• Limit dietary iodine (avoid seaweed, kelp supplements, iodine‑rich salts).
• Maintain adequate calcium and vitamin D intake if antithyroid drugs cause subclinical hypothyroidism later.
• Regular cardiovascular monitoring – ECG, blood pressure.

Living with Jod‑Related Thyrotoxicosis

Managing the condition is a collaborative effort between you, your endocrinologist, and primary‑care provider.

Daily management tips

• Medication adherence – Take thionamides exactly as prescribed; missed doses can precipitate a rebound.
• Track symptoms – Keep a diary of heart rate, weight, sleep quality, and any palpitations.
• Watch your iodine intake – Read food labels; avoid over‑the‑counter supplements unless approved by your doctor.
• Stay hydrated – Helps renal clearance of excess iodine.
• Regular labs – Check thyroid panel every 4–6 weeks until stable, then every 6–12 months.
• Exercise wisely – Light to moderate activity is safe; avoid high‑intensity workouts if you have uncontrolled tachycardia.

Psychosocial considerations

Hyperthyroidism can affect mood and cognition. If you notice anxiety, irritability, or depression that interferes with daily life, discuss it with your provider—counseling or medication adjustments may be needed.

Prevention

While you cannot control environmental iodine exposure completely, several steps reduce the risk of developing jod‑related thyrotoxicosis.

• Screen high‑risk patients before giving iodinated contrast or amiodarone—obtain baseline TSH.
• Use the lowest effective iodine dose for imaging studies.
• Educate patients with multinodular goiter or latent Graves disease about the dangers of high‑iodine supplements.
• Implement public‑health policies to avoid sudden iodine fortification in populations with borderline deficiency.
• Encourage regular thyroid check‑ups for individuals living in iodine‑deficient regions.

Complications

If left untreated, persistent thyrotoxicosis can lead to serious health problems.

• Cardiac complications – Atrial fibrillation, heart failure, or even sudden cardiac death.
• Thyroid storm – A life‑threatening hypermetabolic crisis (see emergency section).
• Bone loss – Accelerated osteoporosis, especially in post‑menopausal women.
• Psychiatric issues – Severe anxiety, psychosis, or depression.
• Pregnancy risks – Pre‑term birth, low birth weight, or fetal neurodevelopmental effects if uncontrolled hyperthyroidism is present.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Contrast Media Safety. 2023. https://www.cdc.gov
2. Mayo Clinic. Hyperthyroidism (Overactive Thyroid). Updated 2022. https://www.mayoclinic.org
3. American Thyroid Association. Jod–Basedow Phenomenon. 2021. https://www.thyroid.org
4. NIH National Institute of Diabetes and Digestive and Kidney Diseases. Thyroid Disease. 2023. https://www.niddk.nih.gov
5. Cleveland Clinic. Iodine‑Induced Hyperthyroidism. 2022. https://my.clevelandclinic.org
6. World Health Organization. Guidelines on Iodine Nutrition. 2020. https://www.who.int

```